<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874286</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 16-006453</org_study_id>
    <nct_id>NCT03874286</nct_id>
  </id_info>
  <brief_title>The TOGETHER Project - Liver</brief_title>
  <acronym>TOGETHER</acronym>
  <official_title>The Together Project-Transplant Organ Genomics to Help Prevent Rejection in Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients
      when correlated to liver biopsy results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, observational study utilizing peripheral blood assays that will
      be collected at time points that are considered standard of care at most institutions. 100
      participants will be enrolled in study. Participants will have peripheral blood collected at
      4 months and 12 months after liver transplant, as well as any for cause time points.
      Participants will also have liver biopsies collected at these time points. The results from
      the liver biopsies will be used in correlation with the results from the peripheral blood
      assays.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.</measure>
    <time_frame>3 years</time_frame>
    <description>The primary endpoint for this study is defined as obtaining the results of the RNAseq testing and to determine if an assay for rejection can be developed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.</measure>
    <time_frame>3 years</time_frame>
    <description>The secondary endpoint for this study is defined as obtaining the results of the RNAseq testing and to ascertain whether an assay for detection of disease recurrence can be developed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Liver Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will obtain a liver biopsy at 4 months post transplant and 12 months post transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver Transplant</intervention_name>
    <description>Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsy's are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.</description>
    <arm_group_label>Liver Transplant</arm_group_label>
    <other_name>Liver biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have given informed consent and are willing to comply with the protocol,
             including the use of their peripheral blood specimens and data for subsequent
             research.

          -  Patients with increased risk of rejection. Patients must meet at least one of the
             following criteria:

               1. Autoimmune etiology of the original liver disease (autoimmune hepatitis, primary
                  biliary cirrhosis or primary sclerosing cholangitis)

               2. Recipients of donation-after-cardiac death (DCD) donors

               3. Recipients of simultaneous liver-kidney transplantation

               4. Positive crossmatch liver transplant (T cell flow crossmatch or B cell flow
                  crossmatch).

                  Exclusion Criteria:

          -  Adult ( â‰¥ = 18 years) renal transplant recipient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Stegall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah M Majerus</last_name>
    <phone>507-255-3940</phone>
    <email>majerus.leah@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nong Yowe Braaten</last_name>
    <phone>507-538-9617</phone>
    <email>braaten.nong@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela S Eyshou</last_name>
      <phone>480-342-3906</phone>
      <email>Eyshou.Angela@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Adyr A Moss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel A. Espinoza</last_name>
      <phone>904-783-8855</phone>
      <email>espinoza.joel@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kristopher P Croome, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah M Majerus</last_name>
      <phone>507-255-3940</phone>
      <email>majerus.leah@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nong Yowe Braaten</last_name>
      <phone>507-538-9617</phone>
      <email>braaten.nong@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark D Stegall, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mark Stegall</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Liver Transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

